ARDS in COVID-19 Patients Phase I Study

ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA). Patients received either one or two doses ofContinue reading “ARDS in COVID-19 Patients Phase I Study”

FDA Approved Phase II Clinical Trial | ARDS in COVID-19 Patients

Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for “A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients with Moderate to Severe Lung Injury due to COVID-19.” The study will enrollContinue reading “FDA Approved Phase II Clinical Trial | ARDS in COVID-19 Patients”

Pulthera to Raise $100M for Further Development of ARDS Therapeutic in COVID-19 Patients

Pulthera is raising $100 million dollars to advance the following objectives: Complete the FDA approved Phase II-A clinical trial for COVID-19 Cytokine Storm Blocker Implement Phase II-B / Phase III clinical trial for ARDS in COVID-19 patients Accelerate commercial manufacturing capabilities Advance the clinical application of at least one other lung-related medical condition beyond ARDSContinue reading “Pulthera to Raise $100M for Further Development of ARDS Therapeutic in COVID-19 Patients”